Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "ANDA"

2088 News Found

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Diagnostic Center | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease


SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
News | May 03, 2025

SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification

This significant milestone enhances our global regulatory standing


Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Drug Approval | May 03, 2025

Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,


Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
News | May 01, 2025

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025


Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Biopharma | April 28, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide


CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Drug Approval | April 28, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein


Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
News | April 28, 2025

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025


Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical
News | April 26, 2025

Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical

The closing of the Block Acquisition is now expected to be completed by Q3 2025


Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion
Drug Approval | April 24, 2025

Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion

Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K